T helper 17 cells, induced by the master transcription factor RORgt, play a key role in the pathogenesis of many autoimmune diseases, including experimental autoimmune uveitis (EAU), an animal model of human uveitis (1) (2) (3) . It is generally believed that IL-6 and TGF-b induce the differentiation of Th17 cells. However, Th17 cells induced by this cytokine combination coproduce IL-17 and IL-10, do not induce autoimmune inflammation in vivo, and were called nonpathogenic Th17 cells (4) (5) (6) . To acquire pathogenicity in vivo, Th17 cells need to be either generated in the presence of IL-23 (4) or to be stimulated with IL-1b, IL-6, and IL-23 triggering IL-23R expression (5) . IL-23R signaling is required for the pathogenicity of Th17 cells in vivo (6, 7) . The development of pathogenic Th17 cells is orchestrated by a complex network of signaling pathways and transcriptional regulators in T cells (8, 9) . Although the involvement of T cell-intrinsic pathways has been studied extensively, how pathogenic Th17 development is shaped by extrinsic signals derived from the innate immune system is relatively less understood.
TLRs bridge the cross-talk between innate and adaptive immunity, primarily via the activation of dendritic cells (DCs). Upon activation, DCs drive Th1 or Th17 cell differentiation by providing antigenic, costimulatory, and cytokine signals (10) . TLRs were reported to differentially regulate pathogenic Th responses. Shi et al. (11) demonstrated that activation of TLR4 with LPS preferentially stimulates IL-17 production, whereas ligation of TLR9 and TLR3 using CpG or polyinosinic-polycytidylic acid [poly(I:C)] primarily stimulates pathogenic Th1 cells in ocular autoimmunity. Among the TLR family, TLR7 is activated by ssRNAs and is strongly expressed by DCs. TLR7 was implicated in a variety of autoimmune disorders (12) (13) (14) , and engagement of TLR7 endows human DCs with the ability to regulate the effector function of Th17 cells (15, 16) . Recently, targeting cell surface TLR7 in DCs was shown to be a promising strategy for treating autoimmune diseases (17) . However, little is known about the mechanism by which TLR7 engagement regulates interphotoreceptor retinoid-binding protein (IRBP)-specific Th17 cells in EAU. More recently, a high copy number of TLR7 was shown to be associated with increased risk for uveitis in humans (18) , suggesting the importance of determining the underlying contribution of TLR7 to cellular signals and interactions in the development of EAU.
MAPK signaling is among the critical pathways activated by innate stimuli in DCs. MAPKs, comprising ERK, JNK and p38, represent fundamental mechanisms for cellular responses to various extracellular signals (19, 20) . Excessive activation of MAPKs is involved in autoimmune diseases, and inhibitors of these pathways were evaluated as new therapeutic approaches in autoimmune diseases (21, 22) . Recent work identified the function of intrinsic ERK phosphorylation in T cells, including an involvement in Th17 development (23, 24) . However, whether ERK regulates the cross-talk between innate and adaptive immune responses in EAU remains largely unknown.
CL097 is a potent TLR7 agonist in mice (25) (26) (27) (28) . In the current study, we addressed the role of TLR7 engagement in EAU development and associated mechanisms using a well-established EAU model. We found that TLR7 ligation enhanced EAU development by increasing the generation of Th17 effector cells. Moreover, TLR7 ligation promoted Th17 cell development by enhancing RORgt expression. Importantly, we demonstrated that TLR7 engagement led to enhanced DC-mediated Th17 responses, primarily via modulation of ERK activity in DCs.
Materials and Methods

Animals and reagents
B10RIII mice (8 wk old) were purchased from the Jackson Laboratory (Bar Harbor, ME), and female C57BL/6 (B6) mice (10 wk) were purchased from Vital River Laboratory Animal Technology (Beijing, China). All procedures were carried out in accordance with the regulations stipulated by the Animal Use and Protection Committee at Tianjin Medical University and conformed to The Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision research. A truncated form of IRBP peptide [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] was synthesized and purified by Sangon (Shanghai, China). Mycobacterium tuberculosis strain H37RA was obtained from Difco (Detroit, MI). Pertussis toxin (PTX) was purchased from Sigma (St. Louis, MO). Recombinant murine IL-12 and IL-23 were purchased from R&D Systems (Minneapolis, MN). FITC-or PE-conjugated Abs against mouse IL-17, IFN-g, CD11c, CD25, MHC class II (MHCII), CD69, and Foxp3 were purchased from BioLegend (San Diego, CA). FITC-conjugated CD40 and CD80 were obtained from BD Biosciences (San Jose, CA). The p38 inhibitor SB203580 and JNK inhibitor SP600125 were purchased from Sigma. The ERK inhibitor U0126, anti-phospho-p38 Ab (3D7), antiphospho-SAPK/JNK Ab (G9), and anti-phospho-ERK1/2 Ab (E10) were purchased from Cell Signaling Technology (Danvers, MA). The mouse TLR-2 agonist PGN, TLR-4 agonist LPS, TLR-3 agonist poly(I:C), TLR7 agonist CL097, and TLR9 agonist CpG were obtained from InvivoGen (San Diego, CA).
Induction of EAU and adoptive transfer
For active induction of EAU, mice were immunized s.c. at six sites on the tail base and flank with 150 ml of emulsion containing uveitogenic peptide. The uveitogenic peptide consisting of aa 1-20 of human IRBP (IRBP [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] ; 150 mg per mouse) or aa 161-180 of human IRBP (IRBP [161] [162] [163] [164] [165] [166] [167] [168] [169] [170] [171] [172] [173] [174] [175] [176] [177] [178] [179] [180] ; 75 mg per mouse) was used for B6 and B10RIII mice, respectively. The peptides were emulsified in CFA, IFA, or IFA containing the TLR7 ligand CL097. Doses of CL097 used for in vivo immunization were 50, 100, or 150 mg per mouse. Concurrently, 200 ng of PTX (Sigma) was injected i.p.
For adoptive transfer, recipient mice were injected i.p. with 2 3 10 6 activated T cells, prepared as described previously (29, 30) .
Scoring of EAU
Mice were examined three times a week for clinical signs of EAU by indirect fundoscopy. The pupils were dilated with 0.5% tropicamide and 1.25% phenylephrine hydrochloride ophthalmic solutions, and fundoscopic grading of disease was performed using the scoring system reported by Thurau et al. (31) . For histopathologic evaluation, whole eyes were collected at the end of the experiment, fixed in 4% paraformaldehyde in PBS, and embedded in paraffin. Five-micrometer sections were cut through the papillary optic nerve plane and stained with standard H&E. The presence or absence of disease was evaluated by blind observers who examined six sections cut at different levels for each eye. The severity of EAU was graded on a scale of 0 to 4, based on cellular infiltration and structural changes (32) .
Generation of bone marrow-derived DCs
Bone marrow-derived DCs (BMDCs) were generated as described previously (22) . In brief, bone marrow cells were flushed from the femurs and tibiae of B6 mice. The cells (1 3 10 6 ) were cultured in 24-well plates in medium supplemented with 10 ng/ml of GM-CSF and 10 ng/ml of rIL-4 (both from R&D Systems). Nonadherent cells were removed carefully, and fresh medium was added every 2 d. On day 7, nonadherent cells were collected for phenotyping. In some experiments, DCs were preincubated with SB203580, U0126, or SP600125 for 1 h and then with CL097. Because these inhibitors were dissolved in DMSO, DCs incubated with DMSO alone were used as a control.
DC isolation
Single-cell suspensions prepared from spleens of mice immunized with IFA/Ag or IFA/Ag+CL097 were incubated for 10 min at 4˚C with PEconjugated anti-mouse CD11c Ab and then for 15 min at 4˚C with anti-PE MicroBeads (Miltenyi Biotec, Bergisch Gladbach, Germany). CD11c + cells were enriched using MACS cell separation, following the manufacturer's instructions (Miltenyi Biotec). The purity of the isolated cell fraction was determined by flow cytometric analysis using FITCconjugated anti-CD11c Ab (BioLegend).
Real-time quantitative RT-PCR
Total RNA from cells was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA). The first-strand cDNA was synthesized with a reverse transcription kit (Fermentas, Burlington, ON, Canada). All gene transcripts were analyzed by quantitative RT-PCR (Q-PCR) with SYBR Green Master Mix using an ABI 7900 HT Sequence Detection System (both from Applied Biosystems, Foster City, CA). Gene-specific primers for Q-PCR are listed in Table I . GAPDH was used as endogenous control in all experiments. For each sample, the relative abundance of target mRNA was calculated from the obtained DCt values for target and the endogenous reference gene GAPDH using the following formula: relative mRNA expression = 2
[DCt(control) 2 DCt(target)] .
Intracellular staining and ELISA
For intracellular staining, cells were exposed to 50 ng/ml of PMA, 1 mg/ml of ionomycin, and 1 mg/ml of brefeldin A (Sigma) for 4 h and then were washed, fixed, permeabilized overnight with buffer (Cytofix/Cytoperm; eBioscience, San Diego, CA), intracellularly stained with Abs, and analyzed on a flow cytometer (FACS Calibur; BD Biosciences). The cytokines in the culture supernatants were detected with commercially available ELISA kits (R&D Systems).
Western blot analysis
Total protein was extracted from 2.5 3 10 6 cells. The protein concentrations were assessed using BCA kits (Biorega, Tianjin, China), according to the manufacturer's instructions. The total proteins (50 mg per sample) were heated to 100˚C for 10 min, loaded into sample wells, resolved on SDSpolyacrylamide gels, and transferred to polyvinylidene difluoride membranes. The membranes were blotted with Abs specific for phospho-p38, phospho-JNK, phospho-Erk (all from Cell Signaling Technology) or b-actin (Santa Cruz Biotechnology, Santa Cruz, CA) and an HRP-linked secondary Ab. Signals were detected with ECL Prime Western blotting Detection Reagent (GE Healthcare), according to the manufacturer's instructions. The bands were scanned with a Multispectral Imaging System (UVP, Upland, CA) and analyzed by Quantity One software (Bio-Rad, Hercules, CA).
DC administration
Bone marrow-derived DCs from B6 mice were incubated with CL097 (2.5 mg/ml) for 24 h and then CL097-treated DCs (CL097-DCs) or untreated DCs (5 3 10 4 cells/0.1 ml per mouse) were injected i.p. into B6 mice on the day of immunization.
Statistical analysis
All experiments were performed at least three times. The figures show results from a representative experiment. Data are presented as mean 6 SD and were analyzed with GraphPad Prism 5.0. The two-tailed Student t test was used to determine statistical significance; p values , 0.05 were considered statistically significant.
Results
TLR7 engagement on DCs, but not on T cells, enhances IRBP-specific Th17 responses in vitro
We first compared the effect of different TLR agonist-stimulated DCs on IRBP-specific Th17 responses. BMDCs stimulated or not with different TLR agonists, including PGN (TLR2), poly(I:C) (TLR3), LPS (TLR4), CL097 (TLR7), and CpG (TLR9), were cocultured with purified IRBP-specific T cells isolated from immunized B6 mice under Th17-polarizing conditions in the presence of immunizing Ag. Five days later, T cells were analyzed for intracellular IL-17 and IFN-g expression by flow cytometry (FACS). As shown in Fig. 1A and 1B, the percentages of Ag-specific IL-17 + T cells were increased significantly in the groups treated with LPS, PGN, or CL097 (16.8, 15.9, and 14.6%, respectively) and were increased slightly in the poly(I:C)-treated group (10.9%) compared with the control group (7.5%); no significant difference was noted in the CpG-treated group (7.6%). In contrast, the percentage of IFN-g + T cells did not change profoundly among these groups. Cytokine
The Journal of Immunology 3821 assay by ELISA showed that the production of IL-17 was increased significantly by treatment with LPS, PGN, poly(I:C), or CL097 but not CpG (Fig. 1C ). These data indicate that stimulation of TLR2, TLR4, and TLR7 was more effective than other TLRs at enhancing Th17 responses, which is in line with the report by Shi et al. (11) showing that LPS and PGN, but not CpG, preferentially stimulate IL-17 production. A dose-titration assay showed that CL097 increased IL-17 and IFN-g production in a dose-dependent manner with significant effect at doses . 2.5 mg/ml (Fig. 1D ). TLR7 is also expressed at low levels in CD4 + T cells (32) . Therefore, we examined whether CL097 directly activated autoreactive T cells. To address this, T cells isolated from immunized mice were preincubated or not with CL097, PGN, or LPS for 12 h, washed, and restimulated with Ag in the presence of APCs under Th17-polarizing conditions; IL-17 secretion was tested 48 h after coculture. As shown in Fig. 1E , IL-17 production of CL097-treated and untreated T cells was similar, whereas T cells preincubated with PGN or LPS produced significantly higher levels of IL-17 compared with untreated T cells (Fig. 1E) . Further assays showed that CL097-treated T cells did not express increased levels of surface CD69 (Fig. 1F) .
CL097 treatment accelerates the development of EAU
Given that enhanced IRBP-specific Th17 responses were induced by CL097-DCs, we next determined whether CL097 could facilitate the development of EAU. B10RIII mice were immunized with the uveitogenic peptide IRBP 161-180 emulsified in IFA, IFA containing CL097, or CFA. EAU scores were monitored by fundoscopy, followed by pathologic examination. As shown in Fig. 2A , mice immunized with IRBP/IFA failed to develop EAU. In contrast, addition of CL097 to IFA during immunization significantly enhanced susceptibility to EAU. In addition, mice treated with 50 mg of CL097 developed significantly less severe EAU than did those treated with 100 or 150 mg. Histological examination of H&E-stained sections showed increased cellular infiltration, disorganized photoreceptors, and thickened choroid in the eye of CL097-treated mice compared with the IFA/IRBP mice (Fig. 2C) . ELISA assays showed that T cells isolated from IFA/Ag+CL097 immunized mice produced significantly larger amounts of IL-17 and IFN-g compared with those from IRBP 161-180 /IFA mice (Fig. 2B) .
CL097 promotes the expression of Th17 lineage-associated genes and generation of Th17 and Th1 cells via DCs in immunized mice
Because Th17 and Th1 autoreactive T cells contribute to the development of EAU (33) APCs under Th17-or Th1-polarizing conditions. Supernatants were harvested for analysis of cytokine secretion by ELISA, and T cells were collected for analysis of intracellular IL-17 and IFN-g expression by FACS. As shown in Fig. 3A and 3B, mice treated with IRBP 1-20 /IFA+CL097 had significantly higher percentages of IL-17 + and IFN-g + T cells compared with the IRBP/IFA group (12.6% versus 0.3% and 7.6% versus 4.2%, respectively). In parallel, the production of IL-17 and IFN-g by IRBP-specific T cells was increased significantly in the CL097 group compared with the IFA group (Fig. 3C) . These results indicate that TLR7 activation promotes Th1 and Th17 responses in vivo.
To determine whether CL097 enhanced Th1 and Th17 autoimmune responses in EAU by affecting DC functions, we compared the Th1-and Th17-stimulatory activity of DCs isolated from mice treated with IRBP/IFA or Ag/IFA+CL097. Splenic DCs isolated from the spleens of IRBP/IFA and IRBP/IFA+CL097 mice were incubated for 48 h with responder T cells from immunized B6 mice, and cytokine levels in the supernatants were measured by ELISA. As shown in Fig. 3D + DCs compared with IRBP/IFA-treated mice (Fig. 3E) . Because the CD25 + DC subset is known to have a strong stimulatory effect on Th17 cells (34), we also examined whether CL097 administration would affect the differentiation of CD25 + DCs. To this end, freshly isolated splenic APCs from IRBP/ IFA-or IRBP/IFA+CL097-treated mice were tested for coexpression of CD25 and CD11c by flow cytometry. As seen in Fig. 3F , the percentage of CD25 + DCs was greatly increased (1%) in IRBP/IFA+ CL097-treated mice compared with IRBP/IFA-treated mice (0.1%).
To further determine the mechanisms by which CL097 enhanced the autoimmune Th cell responses, we compared gene expression of the lineage-related transcription factors and cytokines in autoreactive T cells from immunized mice treated or not with CL097. As shown in Fig. 3G , T cells from the IRBP/IFA+CL097-treated group had significantly higher mRNA expression of IL-17, RORgt, T-bet, GM-CSF, IFN-g, and IL-23R than did those from the IRBP/IFA group, whereas the expression of IL-21 did not change significantly between these two groups. 
CL097 promotes the maturation of DCs and enhances the expression of Th17-polarizing cytokines in DCs via MAPKs
Given that DC maturation plays an important role in the polarization of Th cells (35), we examined whether CL097 affected DC maturation and function. We first assessed the expression of MHCII and costimulatory molecules in unstimulated or CL097-DCs by flow cytometry. The data showed that the expression of MHCII, CD80, CD86, and CD40 was increased in CL097-DCs (Fig. 4A) .
Because DC-produced cytokines, such as IL-23, IL-1b, and IL-6, strongly affect Th cell development (36, 37), we next explored whether TLR7 activation affected the expression of these cytokines in DCs. DCs were cultured for 4-24 h in the absence or presence of CL097, and cells were subjected to Q-PCR. As indicated in Fig. 4B , CL097 treatment significantly enhanced IL-1b, IL-23, IL-6, and IL-12 gene expression in DCs (Table I ). Kinetic analysis revealed that the expression of IL-23, IL-12, and IL-1b genes in CL097-DCs reached peak levels at 4 h after stimulation, whereas the maximal expression of IL-6 was observed at 8 h.
Previous work suggested that MAPKs are potent inducers of TLR-mediated IL-6, IL-1b, and IL-23 production by DCs (36, 38) . To determine the potential role of these MAPKs in CL097-induced proinflammatory cytokine production by DCs, the phosphorylation levels of MAPKs in CL097-DCs were detected by Western blot. As shown in Fig. 4C , CL097 induced a dramatic phosphorylation of ERK at 15 min after treatment, a modest phosphorylation of JNK at 15 min, 30 min, and 1 h, and a weak phosphorylation of p38 at 15 min and 1 h. To further assess the role of MAPK activation in the observed cytokine gene expression changes induced by CL097 in DCs, we used well-known pharmacological inhibitors of these MAPKs. DCs were treated with SP600125 (JNK inhibitor), SB203580 (p38 inhibitor), or U0126 (ERK inhibitor) for 1 h and then stimulated with CL097 for 4 h. As shown in Fig. 4D , p38-specific inhibitor significantly attenuated CL097-induced IL-6 and IL-1b mRNA expression, whereas it had a slight inhibitory effect 
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ERK signaling is involved in IL-17 production by uveitogenic T cells mediated by CL097-DCs
To further test whether MAPKs are involved in the ability of CL097-DCs to drive Th17 responses, DCs were treated or not with specific p38, ERK, and JNK inhibitors (SB203580, U0126, or SP600125, respectively) for 1 h before CL097 stimulation, washed, and cocultured with IRBP-specific T cells in the presence of Ag. The ability of CL097-DCs to induce enhanced intracellular IL-17 expression (Fig. 5A , 5B), increased secretion of IL-17 (Fig. 5D) , and elevated mRNA expression of Th17-associated genes (Fig. 5C) was almost completely blocked when ERK was inhibited. In contrast, inhibition of p38 or JNK only partially reduced IL-17 production and Th17-related gene expression induced by CL097 in the same setting.
CL097-stimulated DCs enhance IRBP-specific Th17 responses and the ability of IRBP-specific Th17 cells to induce EAU
Next, we evaluated whether CL097-DCs influenced Th17 development in vivo. DCs treated or not with CL097 were adoptively transferred i.p. to B6 mice on the day of immunization. At 13 d postimmunization, uveitogenic T cells were isolated and restimulated with IRBP [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] and APCs under nonpolarizing conditions in the presence of Ag. As shown in Fig. 6A and 6B, the percentages of IL-17 + T cells and the secretion of IL-17 and IFN-g increased significantly in mice injected with CL097-DCs in comparison with mice given injection of DCs. Further Q-PCR analysis revealed that the expression of IL-17, ROR-gt, T-bet, and IFN-g was also upregulated significantly in freshly isolated uveitogenic T cells from mice given injections of CL097-DCs (Fig. 6C) .
To determine whether CL097-DCs also affect the pathogenic activity of activated Th17 cells, T cells were isolated from spleen and draining nodes of immunized B6 mice injected with DCs or CL097-DCs. After 48 h of in vitro stimulation with Ag and APCs under Th17-polarizing conditions, the activated T cells were adoptively transferred to naive B6 mice, and EAU scores were monitored by fundoscopy. As shown in Fig. 6D , T cells from CL097-DCtreated mice induced more severe EAU in recipient mice than did those from DC-treated mice.
CL097 treatment reduces the percentages of regulatory T cells in vivo
An enhanced immune response could be due to reduced percentages of regulatory T cells (Tregs). To examine this possibility in our system, we examined the proportions of CD4 + Foxp3 + Tregs in the T cells from the spleen and lymph nodes of IFA/Ag or IFA/ Ag+CL097 immunized mice. As shown in Fig. 7A and 7B, the percentage of CD4 + Foxp3 + T cells was decreased significantly in the T cells from CL097-treated mice compared with untreated mice (4.1 6 0.16% versus 5.7 6 0.32%, respectively).
We also examined the effect of CL097-treated DCs on Treg development in vivo. CL097-DCs or untreated DCs were adoptively transferred i.p. to B6 mice on the day of immunization. T cells were isolated 13 d later, and Foxp3 expression was determined by FACS. As indicated in Fig. 7C and 7D, mice injected with CL097-DCs displayed significantly reduced proportions of Tregs compared with mice injected with DCs (2.36 6 0.33% versus 3.83 6 0.15%, respectively).
Discussion
TLRs are key players in autoimmune disorders. In this study, we explored the ability of different TLR ligand-activated DCs to modulate uveitogenic Th17 development and found that TLR7 ligation significantly promoted autoreactive Th17 responses by enhancing IL-17 and RORgt expression in EAU. Our results showing that TLR7 activation enhanced the clinical signs of EAU by promoting Ag-specific CD4 + T cell responses are in agreement with most recent findings in other experimental models of autoimmune diseases, such as autoimmune diabetes and multiple sclerosis (25, 39, 40) .
Our finding that engaging TLR7 on DCs led to DCs with an increased ability to promote Th17 responses is consistent with several previous reports (15, 41, 42) . However, the TLR7 agonist SA-2 is capable of suppressing the IL-17 response by eliciting IL-10 and IL-10-inducing cytokine prodution by DCs (16) . Hence, it is likely that the effect of TLR7 activation on Th17 responses might be influenced by multiple factors, such as the type of TLR7 ligands, the dosages and timing of administration, or a combination of these. In addition to their ability to regulate adaptive immunity indirectly through stimulating innate responses, TLRs were shown to directly modulate the function of T cells. TLR2 and TLR4 signaling in CD4 + T cells was reported to directly promote Th17 responses (43, 44) . Our results are in accordance with these reports, showing that TLR4 and TLR2 ligation in T cells significantly enhanced IL-17 production in autoreactive T cells. A recent publication by Dominguez-Villar et al. (45) demonstrated that engagement of TLR7 expressed on human CD4 + T cells reduced IL-17 production in HIV infection. However, in the EAU model, we found that TLR7 engagement on autoreactive T cells did not significantly affect T cell activation and IL-17 production. The discrepancy in these findings may be due to different experimental setting or The development of effector Th17 cells is primarily related to the induction of their master transcriptional factor, RORgt (46) . Our studies showed that CL097 treatment significantly upregulated mRNA expression of RORgt in uveitogenic T cells, suggesting that it affects Th17 lineage commitment in vivo. By upregulating expression of the Th1-specific transcription factor T-bet, CL097 concurrently enhanced Ag-specific Th1 differentiation in vivo, in line with data reported by other investigators (47) . In addition, CL097 treatment significantly upregulated GM-CSF and IL-23R expression, which is essential for the pathogenesis of Th17 and Th1 cells in autoimmune disease (6, 48) . Given that Th1 and Th17 responses are involved in the pathogenesis of EAU, it is likely that manipulation of TLR7 and its signal pathways will offer a new therapeutic approach for the treatment of related human disease.
Cytokine production by DCs is necessary for Th cell polarization. IL-6, IL-1b, and IL-23, which are primarily produced by DCs, are critically involved in the initiation, expansion, and stabilization of pathogenic Th17 development, respectively (11, 49) . We found that CL097 significantly promoted the expression and secretion of IL-6, IL-1b and IL-23 by DCs, suggesting that cytokine changes in DCs induced by CL097 might form a favorable milieu for Th17 cell development. Indeed, CL097-DCs significantly promoted the generation of IRBP-specific Th17 cells in vitro, CD11c + DCs from Ag/IFA+CL097-treated mice exhibited an increased ability to promote IL-17 production, and injection of CL097-DCs significantly enhanced autoreactive Th17 responses in EAU mice. It was reported that 10% of splenic CD11c + DCs express CD25, and CD25 + DCs are crucial for Th17 responses in EAU mice (34) . We also observed that CL097-treated EAU mice displayed increased percentages of CD25 + DCs compared with untreated ones, and a significant percentage of BMDCs expressed higher CD25 when the culture medium was supplemented with CL097 (2.5 mg/ml) (data not shown), suggesting that CL097 treatment may enhance differentiation of CD25 + DCs and, hence, lead to increased Th17 responses. However, more research is needed to unravel the relationship between the increased generation of CD25 + DCs and the enhanced autoreactive Th17 responses in CL097-treated mice.
MAPK signaling pathways are central for DC activation. MAPKs were shown, in various systems, to influence cytokine secretion by DCs, including mediating the expression of Th17-polarizing cytokines IL-1b, IL-23, and IL-6 (36, 50) . Our results showed that CL097 induced the activation of ERK, JNK, and p38 MAPKs in DCs. Using specific pharmacological MAPK inhibitors, we found that p38 participated in CL097-induced IL-6 and IL-1b, but not IL-23, mRNA expression; JNK was involved in IL-6, but not IL-1b and IL-23, mRNA expression; and ERK was responsible for upregulated expression of IL-1b and IL-23, but not IL-6, induced by CL097. Taken together, these results indicate that JNK, p38, and ERK MAPKs are activated by CL097 treatment but may play different roles in CL097-mediated cytokine production by DCs. Inhibition of ERK induced a trend toward reduced IL-6 expression, but it was without statistical significance in our system. This observation was unexpected, because previous reports showed that ERK activation induced by PGN or ok-432 significantly upregulated IL-6 expression in DCs or human monocytes (36, 51) . In response to CL097, MAPKs are phosphorylated and activate the transcription factor AP-1 (52) , which can enhance the activation of IL-23, IL-1b, and IL-6 promoters, resulting in increased expression of IL-23, IL-1b, and IL-6 in DCs.
It is interesting to note that blockade of ERK, but not p38 or JNK, markedly suppressed CL097-DC-induced autoreactive Th17 responses, suggesting that CL097 promotes IL-17 expression in developing uveitogenic T cells primarily via the ERK pathway. This is consistent with a previous report showing that ERK is responsible for augmented Th17 responses induced by LPStreated DCs (53) . Nevertheless, the roles of ERK signaling in the regulation of Th17 development have become controversial. Inhibition of ERK in T cells by U0126 was reported to promote Th17 cell development under Th17 conditions (54) . In contrast, a recent study by Liu et al. (24) demonstrated that blockage of T cell-intrinsic ERK signaling, using ERK inhibitor PD98059 or U0126, leads to reduced Th17 responses. U0126 may serve as a stronger DNA demethylation reagent and activate Th17-related gene expression under certain conditions (e.g., rora gene, whose expression is inversely regulated by CpG methylation) (24) . This may explain, in part, the disparity between these reports. CD4 + CD25 + Tregs were demonstrated to play an important role in controlling the occurrence of autoimmune diseases (55) (56) (57) . Activated Tregs prevent or attenuate EAU (58) (59) (60) . Dysfunction of Tregs also was reported in active uveitis patients (60) (61) (62) . We observed a significant decrease in Tregs in the CL097-treated group compared with the control group, implying an inhibiting effect of TLR7 activation on Treg generation; this is in agreement with recent reports showing that TLR7 activation negatively regulates Tregs (39, 63) . The reduction in the percentages of Tregs may account, in part, for the more severe disease in CL097-treated mice.
In conclusion, we demonstrated that TLR7 ligation positively regulated DC activation by enhancing the production of Th17-polarizing cytokines, such as IL-23, IL-1b, and IL-6, resulting in the enhancement of Th17 development and, thereby, amplifying associated autoimmunity. Our data support previous studies on the critical regulatory function of TLR7 on autoimmune responses and indicate a new molecular mechanism for DC-mediated Th17 responses to CL097 treatment, most likely through positively regulating the activity of ERK.
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